Study offers ongoing TPIP access for lung hypertension patients
NCT ID NCT06939647
First seen Nov 03, 2025 · Last updated May 08, 2026 · Updated 30 times
Summary
This study gives continued access to the inhaled drug TPIP for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD). Only those who finished earlier open-label studies of TPIP can join. The goal is to keep providing the treatment while monitoring safety, not to test a new therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION, INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.